These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25125202)

  • 1. Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside.
    Lewin J; Cullinane C; Akhurst T; Waldeck K; Watkins DN; Rao A; Eu P; Mileshkin L; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):25-32. PubMed ID: 25125202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing the anti-tumour activity of
    Cullinane C; Waldeck K; Kirby L; Rogers BE; Eu P; Tothill RW; Hicks RJ
    Sci Rep; 2020 Jun; 10(1):10196. PubMed ID: 32576907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High clinical and morphologic response using
    Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT).
    Kong G; Thompson M; Collins M; Herschtal A; Hofman MS; Johnston V; Eu P; Michael M; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1831-44. PubMed ID: 24844348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
    Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M
    J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide Receptor Radionuclide Therapy with
    Cullinane C; Jeffery CM; Roselt PD; van Dam EM; Jackson S; Kuan K; Jackson P; Binns D; van Zuylekom J; Harris MJ; Hicks RJ; Donnelly PS
    J Nucl Med; 2020 Dec; 61(12):1800-1805. PubMed ID: 32414949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation therapy of small cell lung cancer with 177Lu-DOTA-Tyr3-octreotate in an animal model.
    Schmitt A; Bernhardt P; Nilsson O; Ahlman H; Kölby L; Maecke HR; Forssell-Aronsson E
    J Nucl Med; 2004 Sep; 45(9):1542-8. PubMed ID: 15347722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial Experience With Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma.
    Kong G; Hofman MS; Murray WK; Wilson S; Wood P; Downie P; Super L; Hogg A; Eu P; Hicks RJ
    J Pediatr Hematol Oncol; 2016 Mar; 38(2):87-96. PubMed ID: 26296147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model.
    Schmitt A; Bernhardt P; Nilsson O; Ahlman H; Kölby L; Forssell-Aronsson E
    Cancer Biother Radiopharm; 2005 Apr; 20(2):231-6. PubMed ID: 15869461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours.
    Kashyap R; Hofman MS; Michael M; Kong G; Akhurst T; Eu P; Zannino D; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):176-85. PubMed ID: 25209134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining [
    Rauch H; Kitzberger C; Janghu K; Hawarihewa P; Nguyen NT; Min Y; Ballke S; Steiger K; Weber WA; Kossatz S
    Eur J Nucl Med Mol Imaging; 2024 Jul; ():. PubMed ID: 39023784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of
    Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
    J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of 5-Fluorouracil with Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression, and Radioligand Binding in Neuroendocrine Tumor Cells In Vitro.
    Jin XF; Auernhammer CJ; Ilhan H; Lindner S; Nölting S; Maurer J; Spöttl G; Orth M
    J Nucl Med; 2019 Sep; 60(9):1240-1246. PubMed ID: 30796167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response.
    Feijtel D; Doeswijk GN; Verkaik NS; Haeck JC; Chicco D; Angotti C; Konijnenberg MW; de Jong M; Nonnekens J
    Theranostics; 2021; 11(2):491-505. PubMed ID: 33391488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
    Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
    De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
    Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of
    Shah RG; Merlin MA; Adant S; Zine-Eddine F; Beauregard JM; Shah GM
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33435224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective Treatment of SSTR2-Positive Small Cell Lung Cancer Using
    Qin S; Yang Y; Zhang J; Yin Y; Liu W; Zhang H; Fan X; Yang M; Yu F
    Mol Pharm; 2023 Nov; 20(11):5543-5553. PubMed ID: 37788300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RYZ101 (Ac-225 DOTATATE) Opportunity beyond Gastroenteropancreatic Neuroendocrine Tumors: Preclinical Efficacy in Small-Cell Lung Cancer.
    Han G; Hwang E; Lin F; Clift R; Kim D; Guest M; Bischoff E; Moran S; Li G
    Mol Cancer Ther; 2023 Dec; 22(12):1434-1443. PubMed ID: 37616528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted radiotherapy with [(90)Y]-SMT 487 in mice bearing human nonsmall cell lung tumor xenografts induced to express human somatostatin receptor subtype 2 with an adenoviral vector.
    Rogers BE; Zinn KR; Lin CY; Chaudhuri TR; Buchsbaum DJ
    Cancer; 2002 Feb; 94(4 Suppl):1298-305. PubMed ID: 11877760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.